RBD219-N1 / Fudan University, Baylor College of Medicine, New York Blood Center, Mymetics - LARVOL DELTA

SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. (PubMed, Hum Vaccin Immunother) - "The vaccines induced IFN-γ IL-6, and IL-10 secretion, among other cytokines. Overall, these data suggest that the RBD219-N1C1 recombinant protein, produced in yeast, is suitable for further evaluation as a human COVID-19 vaccine, in particular, in an Alhydrogel® containing formulation and possibly in combination with other immunostimulants."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL10 • IL6

Evaluating recovery, cost, and throughput of different concentration methods for SARS-CoV-2 wastewater-based epidemiology. (PubMed, Water Res) - "We also evaluated the use of a bovine coronavirus vaccine as a process control and pepper mild mottle virus as a normalization factor. Of the five methods we tested head-to-head, we found that HA filtration with bead beating performed the best in terms of sensitivity and cost. This evaluation can serve as a guide for laboratories establishing a protocol to perform wastewater monitoring of SARS-CoV-2."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases